Navigation Links
Codexis Expands Pharmaceutical Manufacturing Partnerships
Date:2/17/2010

REDWOOD CITY, Calif., Feb. 17 /PRNewswire/ -- Codexis, Inc. today announced two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation. These agreements expand the application of Codexis technology to a broadened pipeline of branded innovator pharmaceutical products.

Under the new agreements, Codexis will apply its proprietary biocatalyst technology to selected therapeutic products in the collaborators' portfolios to reduce cost, increase manufacturing efficiency and lessen environmental impact.  Codexis technology is used at innovator pharmaceutical companies to enable cost-effective manufacturing processes at commercial scale.

Dishman, headquartered in Ahmedabad, India, is a global outsourcing partner manufacturing active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry.  Dishman operates 12 API and intermediate production facilities in India, China, Switzerland and the UK manufacturing products for leading global innovator drug companies worldwide.  Under the terms of the agreement, Codexis and Dishman will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators; Dishman will be Codexis' preferred CMO partner for new opportunities at other innovators.  

AFC, headquartered in Rancho Cordova, CA, is a custom manufacturer of pharmaceutical fine chemicals.  The company specializes in technology using high energetic chemistry and other specific technologies which are advantageous for certain classes of products.  

"These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products.  They will be important as we continue to serve our pharmaceutical customers worldwide," said Alan Shaw, Ph.D., President and Chief Executive Officer.

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.

SOURCE Codexis, Inc.

RELATED LINKS
http://www.codexis.com

'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Cellectar Expands Clinical Management Team
7. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. PAREXEL Expands Global Clinical Pharmacology Capabilities
11. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... June 9, 2017 AirXpanders, Inc. (ASX: AXP) ... the design, manufacture, sale and distribution of the AeroForm® ... progress of its commercial roll-out in the ... more than one hundred (100) medical institutions and health ... offers a needle-free alternative for women who choose reconstructive ...
(Date:6/8/2017)... June 8, 2017  Less than a month ago, ... than 200,000 companies, including hospital networks, in over 150 ... one of the largest online extortion attempts ever recorded. ... market, it is imperative that providers understand where the ... from this — and many other very real cyber ...
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
Breaking Medicine Technology:
(Date:6/22/2017)... California (PRWEB) , ... June 22, 2017 , ... Groove ... spread the word about their high performance silicon wedding bands and all-purpose rings. Whether ... are the active, silicone rings designed just for you. , From the rock face ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work in countries ... where the rule of law has been degraded. The PSC.1 standard was created ...
(Date:6/20/2017)... ... 20, 2017 , ... Connance, a leading provider of healthcare ... predictive analytics drive reimbursement optimization, with a focus on denial management and claims ... “The traditional approach to denied and underpaid claims leaves money on the table ...
(Date:6/20/2017)... ... June 20, 2017 , ... Hayes, Inc., a leading ... eBook titled “ 5 Questions to Ask Before Entering the Maze of Genetic ... Test Evaluation (GTE) team, the book explores the various types of the more ...
(Date:6/20/2017)... ... 2017 , ... HOUSTON – Brazos Towers at Bayou Manor is proud ... options for today’s modern senior. Brazos Towers at Bayou Manor has more than 50 ... offering them the services to support that lifestyle both now and in the future. ...
Breaking Medicine News(10 mins):